

AbbVie vs Bristol Myers Squibb
Large pharmaceutical company with strong cash flow and dividend vs Large pharmaceutical company selling cancer and immune drugs. Which is the better buy for your portfolio in November 2026? Plain-English answer below.
AbbVie built an empire on Humira and is now sprinting to diversify its immunology and oncology pipeline before biosimilar erosion bites, while Bristol Myers Squibb has assembled a formidable cancer drug franchise anchored by Opdivo and Eliquis. Both pharma giants are navigating the same brutal patent cliff cycle and deploying billions in M&A to replenish revenue. AbbVie vs Bristol Myers Squibb puts two of the industry's biggest cash-flow machines side by side to compare their pipeline depth, dividend sustainability, and long-term growth bets.
AbbVie built an empire on Humira and is now sprinting to diversify its immunology and oncology pipeline before biosimilar erosion bites, while Bristol Myers Squibb has assembled a formidable cancer dr...
Why It’s Moving

AbbVie’s Neuroscience and Immunology Franchises Drive Upward Revisions to 2026 Outlook
- The neuroscience franchise delivered 19.5% operational sales growth in Q3, leading AbbVie to increase its 2026 segment sales outlook to $13 billion.
- Immunology sales rose 16.6% in Q3, driven by robust demand for Skyrizi and Rinvoq, which successfully mitigated the ongoing decline of Humira.
- Defensive sectors like healthcare have recently outperformed the S&P 500, with investors paying premiums for stocks that offer stability and consistent dividend growth.

Bristol Myers Squibb Shares Face Scrutiny as Analysts Weigh KarXT Trial Success Against Competitive Pressures
- Preliminary Phase 3 data from the ADEPT program shows that KarXT reduced hallucinations and delusions in patients with psychosis associated with Alzheimer's disease, marking a significant clinical milestone for the pipeline.
- The company reported that growth portfolio revenue rose 12% year over year to $7.7 billion, with eight medicines now annualizing over $1 billion each, demonstrating resilience despite patent expiration headwinds.
- Strategic shifts include the merger of scientific and clinical teams into a unified R&D department effective January 1, 2027, while some analysts continue to view competitor Merck as having superior stock performance and diversified growth drivers.

AbbVie’s Neuroscience and Immunology Franchises Drive Upward Revisions to 2026 Outlook
- The neuroscience franchise delivered 19.5% operational sales growth in Q3, leading AbbVie to increase its 2026 segment sales outlook to $13 billion.
- Immunology sales rose 16.6% in Q3, driven by robust demand for Skyrizi and Rinvoq, which successfully mitigated the ongoing decline of Humira.
- Defensive sectors like healthcare have recently outperformed the S&P 500, with investors paying premiums for stocks that offer stability and consistent dividend growth.

Bristol Myers Squibb Shares Face Scrutiny as Analysts Weigh KarXT Trial Success Against Competitive Pressures
- Preliminary Phase 3 data from the ADEPT program shows that KarXT reduced hallucinations and delusions in patients with psychosis associated with Alzheimer's disease, marking a significant clinical milestone for the pipeline.
- The company reported that growth portfolio revenue rose 12% year over year to $7.7 billion, with eight medicines now annualizing over $1 billion each, demonstrating resilience despite patent expiration headwinds.
- Strategic shifts include the merger of scientific and clinical teams into a unified R&D department effective January 1, 2027, while some analysts continue to view competitor Merck as having superior stock performance and diversified growth drivers.
Investment Analysis

AbbVie
ABBV
Pros
- AbbVie maintains dominant market position in immunology with Skyrizi and Rinvoq driving robust revenue growth.
- Strong balance sheet supports sustained R&D investment and share repurchases amid patent cliffs.
- Humira successors demonstrate high-teens growth potential offsetting legacy product declines.
Considerations
- Ongoing patent expirations for key drugs expose revenue to generic erosion through 2028.
- Regulatory hurdles in obesity portfolio delay potential new growth catalysts.
- High debt levels from past acquisitions elevate financial risk in rising interest environment.
Pros
- Growth products like Eliquis, Reblozyl and Breyanzi deliver strong double-digit sales increases into 2026.
- Attractive 4.5% dividend yield backed by 56-year payment history and recent hikes.
- Pipeline catalysts in 2026 offer substantial upside potential beyond priced-in LOE headwinds.
Considerations
- Legacy portfolio faces 15-17% revenue decline in 2025 from generic competition.
- Loss of exclusivity pressures persist through 2028 with $20-30 billion revenue impact.
- Sell-side consensus holds 'Hold' rating despite recent upgrades amid execution uncertainties.
AbbVie (ABBV) Next Earnings Date
ABBV has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern of releasing results approximately three months after the previous quarter, the next announcement is expected in early February 2027. This upcoming release will cover the fourth quarter and full-year fiscal 2026 performance. Investors should monitor official channels for the precise scheduling confirmation as the date approaches.
Bristol Myers Squibb (BMY) Next Earnings Date
Bristol-Myers Squibb has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern, which typically follows a quarterly cycle of approximately three months after the previous release, the next report is expected in early February 2027. This upcoming disclosure will cover financial results for the fourth quarter and full fiscal year 2026. Investors should monitor official communications for the precise scheduling of this anticipated release.
AbbVie (ABBV) Next Earnings Date
ABBV has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern of releasing results approximately three months after the previous quarter, the next announcement is expected in early February 2027. This upcoming release will cover the fourth quarter and full-year fiscal 2026 performance. Investors should monitor official channels for the precise scheduling confirmation as the date approaches.
Bristol Myers Squibb (BMY) Next Earnings Date
Bristol-Myers Squibb has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern, which typically follows a quarterly cycle of approximately three months after the previous release, the next report is expected in early February 2027. This upcoming disclosure will cover financial results for the fourth quarter and full fiscal year 2026. Investors should monitor official communications for the precise scheduling of this anticipated release.
Buy ABBV or BMY in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.